18-03574-E

March 14 2018

US Securities & Exchange Commission
Office of FOIA and Privacy Act Operations
100 F Street, NE Mail Stop 5100
Washington, DC 20549-5100

RECEIVED

MAR 142018

Office of FOIA Services

Dear FOIA Office:

Under the Freedom of Information Act (FOIA), please send a copy of the following:

A copy of: Exhibit 10.77 to the form 10-Q filed by JAZZ PHARMACEUTICALS INC on November 14, 2008

In the event confidential treatment has not expired provide the specific date for which confidential treatment is still in effect. I do not need a copy of the order. We authorize up to \$61.00 in processing fees. Thank You,

Paul D'Souza Editor - Deals

Clarivate Analytics Friars House, 160 Blackfriars Road London, UK SE1 8EZ

Phone: +44-2074334789 paul.dsouza@clarivate.com



UNITED STATES SECURITIES AND EXCHANGE COMMISSION

STATION PLACE 100 F STREET, NE WASHINGTON, DC 20549-2465

Office of FOIA Services

April 6, 2018

Mr. Paul D'Souza Clarivate Analytics 160 Blackfriars Road London, UK SE18EZ

RE: Freedom of Information Act (FOIA), 5 U.S.C. \S 552

Request No. 18-03274-E

Dear Mr. D'Souza:

This letter is in response to your request, dated March 14, 2018 and received in this office on March 14, 2018, for Exhibit 10.77 to the Form 10-Q filed by Jazz Pharmaceuticals, Inc. on November 14, 2008.

The Commission granted confidential treatment to Exhibit 10.77 to the Form 10-Q under Rule 24b-2 of the Securities Exchange Act of 1934 through November 14, 2018. Since confidential treatment has not expired, we are providing the expiration date from the relevant CT order as requested.

If you have any questions, please contact me directly at andersonc@sec.gov or (202) 551-8315. You may also contact me at foiapa@sec.gov or (202) 551-7900. You also have the right to seek assistance from a FOIA Public Liaison, Ray J. McInerney at (202) 551-7900.

Sincerely,

Clarissa Anderson FOIA Research Specialist

Clarissa Andersox